½ÃÀ庸°í¼­
»óǰÄÚµå
1621344

¼º °¨¿°Áõ Áø´Ü ½ÃÀå : Áúȯ À¯Çü, Áø´Ü ¹æ¹ý, µð¹ÙÀ̽º À¯Çü, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Sexually Transmitted Disease Diagnostics Market by Disease Type, Diagnostic methods, Device Type, End-Users - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 186 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼º°¨¿° Áø´Ü ½ÃÀåÀº 2023³â¿¡ 1,065¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 1,125¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CAGR 5.97%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1,599¾ï 7,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼ºº´(STD) Áø´Ü ½ÃÀåÀÇ ¹üÀ§¿¡´Â HIV, ¸Åµ¶, ÀÓÁú, Ŭ¶ó¹Ìµð¾Æ µî ¼º Á¢ÃËÀ» ÅëÇØ Àü¿°µÇ´Â °¨¿°º´À» ½Äº°ÇÏ´Â µ¥ »ç¿ëµÇ´Â ´Ù¾çÇÑ °Ë»ç¿Í ±â¼úÀÌ Æ÷ÇԵ˴ϴÙ. Áø´Ü¾àÀº °øÁß º¸°Ç¿¡ ÇʼöÀûÀ̸ç, °¨¿°ÀÇ È®»êÀ» ¹æÁöÇϱâ À§ÇØ Á¶±â ¹ß°ß°ú Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áø´Ü¾àÀÇ ¿ëµµ´Â ÀÇ·á ½Ã¼³¿¡¼­ °¡Á¤¿ë °Ë»ç ŰƮ¿¡ À̸£±â±îÁö ´Ù¾çÇϸç, º´¿ø, Ŭ¸®´Ð, °³ÀÎ ¼ÒºñÀÚ¸¦ À§ÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÃÖÁ¾ »ç¿ë ºÐ¾ß¿¡´Â °øÁß º¸°Ç ¿¬±¸¼Ò, ¹Î°£ Ŭ¸®´Ð, ¿¬±¸ ±â°ü µîÀÌ Æ÷ÇԵ˴ϴÙ. ½ÃÀå ¼ºÀåÀº ¼º °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¼ºº´ ÀÎ½Ä ¹× °ü¸®¿¡ ´ëÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡, ½Å¼ÓÇÑ ÇöÀå °Ë»ç ¹× ÇÙ»ê ÁõÆø °Ë»ç¿Í °°Àº °Ë»ç ¹æ¹ýÀÇ ±â¼úÀû Áøº¸¿¡ Å©°Ô ¿µÇâÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº º¸´Ù ½Å¼ÓÇϰí Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇÔÀ¸·Î½á »ç¿ëÀÚ ÆíÀǼºÀ» ³ôÀÌ°í ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ´Â ÀÎ½Ä Á¦°í ÇÁ·Î±×·¥ÀÌ °³¼±µÇ°í Áø´Ü¾à äÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â ½ÅÈï ½ÃÀå¿¡¼­ ãÀ» ¼ö ÀÖ½À´Ï´Ù. Áø´Ü ±â¾÷ ¹× ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿ÍÀÇ Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ÅëÇØ µµ´Þ ¹üÀ§¿Í ¿µÇâ·ÂÀ» °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ¼ºº´¿¡ ´ëÇÑ »çȸÀû ³«ÀÎ, °í°¡ÀÇ Áø´Ü °Ë»ç ºñ¿ë, °øÁߺ¸°Ç °³ÀÔÀ» Á¦ÇÑÇÏ´Â ±ÔÁ¦Àû Àå¾Ö¹° µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áö¿ª °£ ÀÇ·á ÀÎÇÁ¶ó °ÝÂ÷°¡ Á¢±Ù¼º¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÇѰ赵 ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀÌ ÇÊ¿äÇÑ ºÐ¾ß·Î´Â ºñ¿ë È¿À²ÀûÀÌ°í »ç¿ëÇϱ⠽¬¿î ÀçÅà °Ë»ç ¼Ö·ç¼ÇÀÇ °³¹ß, Ä¡·á °èȹÀ» °³ÀÎÈ­Çϱâ À§ÇÑ ÀΰøÁö´ÉÀÇ ÅëÇÕ, °Ë»çÀÇ ¹Î°¨µµ¿Í ƯÀ̵µ Çâ»ó µîÀÌ ÀÖ½À´Ï´Ù. ¿©·¯ °¨¿°º´À» µ¿½Ã¿¡ È®ÀÎÇÒ ¼ö ÀÖ´Â ¸ÖƼÇ÷º½º Áø´Ü¿¡ ´ëÇÑ ¿¬±¸´Â À¯¸ÁÇϸç, ¼ºº´ Áø´Ü ½ÃÀåÀº ±â¼ú Çõ½Å¿¡ ÀÇÇØ ÁÖµµµÇÁö¸¸ »çȸÀû À庮¿¡ °¡·Î¸·Çô ÀÖ´Â ¿ªµ¿ÀûÀÎ ½ÃÀåÀ¸·Î, ±â¾÷µéÀÌ ÀÇ·á ¼­ºñ½º Á¦°øÀÇ ¹®È­Àû ¿ª·®¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÌ·¯ÇÑ °úÁ¦¸¦ È¿°úÀûÀ¸·Î ±Øº¹Çϱâ À§ÇØ Çù·Â °ü°è¸¦ ±¸ÃàÇÒ °ÍÀ» Á¦¾ÈÇß½À´Ï´Ù. Çù·Â °ü°è¸¦ ±¸ÃàÇÒ °ÍÀ» Á¦¾ÈÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 1,065¾ï 3,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 1,125¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 1,599¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 5.97%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¼ºº´ Áø´ÜÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¼ºº´ Áø´Ü ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è ¼ºº´ À¯º´·ü Áõ°¡¿Í È¿°úÀûÀÎ Áø´Ü ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ ´ëµÎµÊ
    • ¼ºº´¿¡ ´ëÇÑ ³«ÀÎÀ» ÁÙÀ̱â À§ÇØ Àü ¼¼°èÀûÀ¸·Î ¼ºº´ °ËÁø ½Ç½Ã Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • STD¿¡ ´ëÇÑ ÃæºÐÇÑ Àνİú ±³À° ºÎÁ·
  • ½ÃÀå ±âȸ
    • STD¿¡ ´ëÇÑ Àνİú ¿¹¹æÀ» À§ÇÑ ÀÚ±Ý Áö¿ø ¹× °øÁߺ¸°Ç Ä·ÆäÀÎ Áõ°¡
    • Â÷¼¼´ë ½ÃÄö¼­ ¹× CRISPR ±â¹Ý Áø´Ü ±â¼ú Çõ½Å
  • ½ÃÀå °úÁ¦
    • ÀǾàǰ ½ÂÀο¡ ´ëÇÑ Á¤ºÎÀÇ ¾ö°ÝÇÑ ±ÔÁ¦¿Í Ä¡·áµÇÁö ¾ÊÀº °¨¿°À¸·Î ÀÎÇÑ ÇÕº´Áõ

Porter's Five Forces: ¼ºº´ Áø´ÜÁ¦ ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÆÄ¾ÇÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¼ºº´ Áø´ÜÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ·Â ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¼ºº´ Áø´Ü ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼®¼º°¨¿°Áõ Áø´ÜÁ¦ ½ÃÀå °æÀï»óȲ ÆÄ¾Ç

¼ºº´ Áø´ÜÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¼ºº´ Áø´ÜÁ¦ ½ÃÀå¿¡¼­ÀÇ ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¼ºº´ Áø´Ü ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

°¨¿°º´ Áø´ÜÁ¦ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

¼ºº´ Áø´Ü ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀïÀû À§Ä¡´Â?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
    • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
      • Á¤Ä¡Àû
      • °æÁ¦Àû
      • »çȸÀû
      • ±â¼úÀû
      • ¹ýÀû
      • ȯ°æÀû

    Á¦6Àå ¼º°¨¿°Áõ Áø´Ü ½ÃÀå : Áúȯ À¯Çüº°

    • ¼¼±Õ¼º Áú¿°
    • Ä­µð´Ù Áú¿°
    • Ŭ¶ó¹Ìµð¾Æ?Æ®¶óÄÚ¸¶Æ¼½º/ÀÓ±Õ
    • ¼º±â »ç¸¶±Í
    • BÇü °£¿°
    • HIV/¿¡ÀÌÁî
    • ¸¶ÀÌÄÚÇö󽺸¶¡¤Á¦´ÏÅ»·ý
    • ¸Åµ¶
    • Æ®¸®Äڸ𳪽ºÁõ

    Á¦7Àå ¼º°¨¿°Áõ Áø´Ü ½ÃÀå Áø´Ü ¹æ¹ýº°

    • Ç׿ø °ËÃâ
    • ºÐÀÚÁø´Ü
    • Ç÷ûÇÐÀû °Ë»ç

    Á¦8Àå ¼º°¨¿°Áõ Áø´Ü ½ÃÀå µð¹ÙÀ̽º À¯Çüº°

    • ½ÇÇèÀåÄ¡
      • Èí±¤µµ ¸¶ÀÌÅ©·ÎÇ÷¹ÀÌÆ® ¸®´õ
      • ¹ÌºÐ±¤»ê¶õÀåÄ¡
      • ÇÃ·Î¿ì »çÀÌÅä¹ÌÅÍ
      • ·¡ÅÍ·² ÇÃ·Î¿ì ¸®´õ
      • ¼­¸Ö »çÀÌŬ·¯-PCR
    • Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î µð¹ÙÀ̽º
      • ÀüÈ­ Ĩ(¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ICT)
      • ½Å¼Ó Áø´Ü ŰƮ

    Á¦9Àå ¼º°¨¿°Áõ Áø´Ü ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

    • Ŭ¸®´Ð
    • Áø´Ü ½ÇÇè½Ç
    • º´¿ø
    • °øÁßÀ§»ý±â°ü
    • ¿¬±¸±â°ü

    Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ¼º°¨¿°Áõ Áø´Ü ½ÃÀå

    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
    • ¹Ì±¹

    Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼º°¨¿°Áõ Áø´Ü ½ÃÀå

    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • Àεµ³×½Ã¾Æ
    • ÀϺ»
    • ¸»·¹À̽þÆ
    • Çʸ®ÇÉ
    • ½Ì°¡Æ÷¸£
    • Çѱ¹
    • ´ë¸¸
    • ű¹
    • º£Æ®³²

    Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¼º°¨¿°Áõ Áø´Ü ½ÃÀå

    • µ§¸¶Å©
    • ÀÌÁýÆ®
    • Çɶõµå
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • À̽º¶ó¿¤
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ³ªÀÌÁö¸®¾Æ
    • ³ë¸£¿þÀÌ
    • Æú¶õµå
    • īŸ¸£
    • ·¯½Ã¾Æ
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ½ºÀ§½º
    • ÅÍŰ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ¿µ±¹

    Á¦13Àå °æÀï ±¸µµ

    • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
    • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
    • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Àü·« ºÐ¼®°ú Á¦¾È

    ±â¾÷ ¸ñ·Ï

    • Abbott Laboratories
    • Astra Biotech Gmbh
    • Becton Dickinson and company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Danaher Corporation
    • Daye Limited
    • Diasorin SpA
    • F. Hoffmann-La Roche Ltd
    • Geneproof
    • Hologic Inc.
    • Jiangsu BioPerfectus Technologies Co., Ltd
    • Liferiver Bio-Tech Corp.
    • MedMira Inc
    • Meridian Bioscience Inc.
    • Mylab Discovery Solutions Pvt. Ltd.
    • OraSure Technologies, Inc.
    • Qiagen Inc
    • Quest Consumer Inc.
    • Sansure Biotech Inc.
    • Seegene Inc.
    • Siemens Healthcare GmbH
    • Thermo Fisher Scientific, Inc.
    LSH 25.01.08

    The Sexually Transmitted Disease Diagnostics Market was valued at USD 106.53 billion in 2023, expected to reach USD 112.56 billion in 2024, and is projected to grow at a CAGR of 5.97%, to USD 159.97 billion by 2030.

    The scope of the Sexually Transmitted Disease (STD) Diagnostics market encompasses the various tests and technologies used to identify infections transmitted through sexual contact, including HIV, syphilis, gonorrhea, chlamydia, and more. Diagnostics are essential for public health, enabling early detection and treatment to prevent the spread of infections. Applications of these diagnostics range from healthcare facilities to home-based testing kits, offering solutions for hospitals, clinics, and individual consumers. End-use segments include public health laboratories, private clinics, and research institutes. Market growth is significantly influenced by rising awareness of sexual health, increased government initiatives for STD awareness and control, and technological advancements in testing methods, such as rapid point-of-care tests and nucleic acid amplification tests. These advancements offer faster and more accurate results, thereby enhancing user convenience and boosting market demand. Potential opportunities lie in emerging markets where awareness programs are improving and the adoption of diagnostics is increasing. Strategic partnerships between diagnostic companies and healthcare providers can enhance reach and impact. However, market growth faces challenges such as social stigma associated with STDs, the high cost of advanced diagnostic tests, and regulatory hurdles that can limit public health intervention efforts. Limitations also include disparity in healthcare infrastructure across regions, affecting accessibility. The best areas for innovation include developing cost-effective and user-friendly home testing solutions, integrating artificial intelligence to personalize treatment plans, and improving sensitivity and specificity of tests. Research into multiplex diagnostics that can identify multiple infections simultaneously is promising. The STD Diagnostics market is dynamic, driven by technological innovation yet hindered by societal barriers, suggesting businesses focus on cultural competence in healthcare delivery and form collaborative relationships to navigate these challenges effectively.

    KEY MARKET STATISTICS
    Base Year [2023] USD 106.53 billion
    Estimated Year [2024] USD 112.56 billion
    Forecast Year [2030] USD 159.97 billion
    CAGR (%) 5.97%

    Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sexually Transmitted Disease Diagnostics Market

    The Sexually Transmitted Disease Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

    • Market Drivers
      • The rising prevalence of sexual diseases worldwide and the need for effective diagnostic solutions
      • Increasing implementation of worldwide screening to reduce the stigma associated with STD
    • Market Restraints
      • Lack of adequate awareness and education about STDs
    • Market Opportunities
      • Increased funding and public health campaigns for STD awareness and prevention
      • Innovations in next-generation sequencing and CRISPR-based diagnostics
    • Market Challenges
      • Stringent government regulations for drug approvals and complications arising from untreated infections

    Porter's Five Forces: A Strategic Tool for Navigating the Sexually Transmitted Disease Diagnostics Market

    Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sexually Transmitted Disease Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

    PESTLE Analysis: Navigating External Influences in the Sexually Transmitted Disease Diagnostics Market

    External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sexually Transmitted Disease Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

    Market Share Analysis: Understanding the Competitive Landscape in the Sexually Transmitted Disease Diagnostics Market

    A detailed market share analysis in the Sexually Transmitted Disease Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

    FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sexually Transmitted Disease Diagnostics Market

    The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sexually Transmitted Disease Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

    Strategy Analysis & Recommendation: Charting a Path to Success in the Sexually Transmitted Disease Diagnostics Market

    A strategic analysis of the Sexually Transmitted Disease Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

    Key Company Profiles

    The report delves into recent significant developments in the Sexually Transmitted Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astra Biotech Gmbh, Becton Dickinson and company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd, Geneproof, Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., MedMira Inc, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., OraSure Technologies, Inc., Qiagen Inc, Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthcare GmbH, and Thermo Fisher Scientific, Inc..

    Market Segmentation & Coverage

    This research report categorizes the Sexually Transmitted Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

    • Based on Disease Type, market is studied across Bacterial Vaginosis, Candidal Vaginitis, Chlamydia Trachomatis/ Neisseria Gonorrhoeae, Genital Warts, Hepatitis B, HIV/AIDS, Mycoplasma Genitalium, Syphilis, and Trichomoniasis.
    • Based on Diagnostic methods, market is studied across Antigen Detection, Molecular Diagnostics, and Serologic Testing.
    • Based on Device Type, market is studied across Laboratory Devices and Point of Care Devices. The Laboratory Devices is further studied across Absorbance Microplate Reader, Differential Light Scattering Machines, Flow Cytometers, Lateral Flow Readers, and Thermal Cyclers - PCR. The Point of Care Devices is further studied across Phone Chips (Microfluidics + ICT) and Rapid Diagnostic Kits.
    • Based on End-Users, market is studied across Clinics, Diagnostic Laboratories, Hospitals, Public Health Agencies, and Research Institutions.
    • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

    The report offers a comprehensive analysis of the market, covering key focus areas:

    1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

    2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

    3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

    4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

    5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

    The report also answers critical questions to aid stakeholders in making informed decisions:

    1. What is the current market size, and what is the forecasted growth?

    2. Which products, segments, and regions offer the best investment opportunities?

    3. What are the key technology trends and regulatory influences shaping the market?

    4. How do leading vendors rank in terms of market share and competitive positioning?

    5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

    Table of Contents

    1. Preface

    • 1.1. Objectives of the Study
    • 1.2. Market Segmentation & Coverage
    • 1.3. Years Considered for the Study
    • 1.4. Currency & Pricing
    • 1.5. Language
    • 1.6. Stakeholders

    2. Research Methodology

    • 2.1. Define: Research Objective
    • 2.2. Determine: Research Design
    • 2.3. Prepare: Research Instrument
    • 2.4. Collect: Data Source
    • 2.5. Analyze: Data Interpretation
    • 2.6. Formulate: Data Verification
    • 2.7. Publish: Research Report
    • 2.8. Repeat: Report Update

    3. Executive Summary

    4. Market Overview

    5. Market Insights

    • 5.1. Market Dynamics
      • 5.1.1. Drivers
        • 5.1.1.1. The rising prevalence of sexual diseases worldwide and the need for effective diagnostic solutions
        • 5.1.1.2. Increasing implementation of worldwide screening to reduce the stigma associated with STD
      • 5.1.2. Restraints
        • 5.1.2.1. Lack of adequate awareness and education about STDs
      • 5.1.3. Opportunities
        • 5.1.3.1. Increased funding and public health campaigns for STD awareness and prevention
        • 5.1.3.2. Innovations in next-generation sequencing and CRISPR-based diagnostics
      • 5.1.4. Challenges
        • 5.1.4.1. Stringent government regulations for drug approvals and complications arising from untreated infections
    • 5.2. Market Segmentation Analysis
      • 5.2.1. Disease Type: Advancements in next-generation sequencing and CRISPR-based diagnostics to cater varied STDs
      • 5.2.2. End-Users: Increasing adoption of STD diagnostics in clinical and hospital settings to cater complicated STD cases
    • 5.3. Porter's Five Forces Analysis
      • 5.3.1. Threat of New Entrants
      • 5.3.2. Threat of Substitutes
      • 5.3.3. Bargaining Power of Customers
      • 5.3.4. Bargaining Power of Suppliers
      • 5.3.5. Industry Rivalry
    • 5.4. PESTLE Analysis
      • 5.4.1. Political
      • 5.4.2. Economic
      • 5.4.3. Social
      • 5.4.4. Technological
      • 5.4.5. Legal
      • 5.4.6. Environmental

    6. Sexually Transmitted Disease Diagnostics Market, by Disease Type

    • 6.1. Introduction
    • 6.2. Bacterial Vaginosis
    • 6.3. Candidal Vaginitis
    • 6.4. Chlamydia Trachomatis/ Neisseria Gonorrhoeae
    • 6.5. Genital Warts
    • 6.6. Hepatitis B
    • 6.7. HIV/AIDS
    • 6.8. Mycoplasma Genitalium
    • 6.9. Syphilis
    • 6.10. Trichomoniasis

    7. Sexually Transmitted Disease Diagnostics Market, by Diagnostic methods

    • 7.1. Introduction
    • 7.2. Antigen Detection
    • 7.3. Molecular Diagnostics
    • 7.4. Serologic Testing

    8. Sexually Transmitted Disease Diagnostics Market, by Device Type

    • 8.1. Introduction
    • 8.2. Laboratory Devices
      • 8.2.1. Absorbance Microplate Reader
      • 8.2.2. Differential Light Scattering Machines
      • 8.2.3. Flow Cytometers
      • 8.2.4. Lateral Flow Readers
      • 8.2.5. Thermal Cyclers - PCR
    • 8.3. Point of Care Devices
      • 8.3.1. Phone Chips (Microfluidics + ICT)
      • 8.3.2. Rapid Diagnostic Kits

    9. Sexually Transmitted Disease Diagnostics Market, by End-Users

    • 9.1. Introduction
    • 9.2. Clinics
    • 9.3. Diagnostic Laboratories
    • 9.4. Hospitals
    • 9.5. Public Health Agencies
    • 9.6. Research Institutions

    10. Americas Sexually Transmitted Disease Diagnostics Market

    • 10.1. Introduction
    • 10.2. Argentina
    • 10.3. Brazil
    • 10.4. Canada
    • 10.5. Mexico
    • 10.6. United States

    11. Asia-Pacific Sexually Transmitted Disease Diagnostics Market

    • 11.1. Introduction
    • 11.2. Australia
    • 11.3. China
    • 11.4. India
    • 11.5. Indonesia
    • 11.6. Japan
    • 11.7. Malaysia
    • 11.8. Philippines
    • 11.9. Singapore
    • 11.10. South Korea
    • 11.11. Taiwan
    • 11.12. Thailand
    • 11.13. Vietnam

    12. Europe, Middle East & Africa Sexually Transmitted Disease Diagnostics Market

    • 12.1. Introduction
    • 12.2. Denmark
    • 12.3. Egypt
    • 12.4. Finland
    • 12.5. France
    • 12.6. Germany
    • 12.7. Israel
    • 12.8. Italy
    • 12.9. Netherlands
    • 12.10. Nigeria
    • 12.11. Norway
    • 12.12. Poland
    • 12.13. Qatar
    • 12.14. Russia
    • 12.15. Saudi Arabia
    • 12.16. South Africa
    • 12.17. Spain
    • 12.18. Sweden
    • 12.19. Switzerland
    • 12.20. Turkey
    • 12.21. United Arab Emirates
    • 12.22. United Kingdom

    13. Competitive Landscape

    • 13.1. Market Share Analysis, 2023
    • 13.2. FPNV Positioning Matrix, 2023
    • 13.3. Competitive Scenario Analysis
      • 13.3.1. British startup launches tampon that offers STI screening
      • 13.3.2. BioPerfectus Launches New PCR Kits for Sexually Transmitted Diseases Diagnostic Solution
      • 13.3.3. Mylab Launches rapid tests for sexually transmitted diseases
    • 13.4. Strategy Analysis & Recommendation

    Companies Mentioned

    • 1. Abbott Laboratories
    • 2. Astra Biotech Gmbh
    • 3. Becton Dickinson and company
    • 4. Bio-Rad Laboratories, Inc.
    • 5. bioMerieux SA
    • 6. Danaher Corporation
    • 7. Daye Limited
    • 8. Diasorin S.p.A
    • 9. F. Hoffmann-La Roche Ltd
    • 10. Geneproof
    • 11. Hologic Inc.
    • 12. Jiangsu BioPerfectus Technologies Co., Ltd
    • 13. Liferiver Bio-Tech Corp.
    • 14. MedMira Inc
    • 15. Meridian Bioscience Inc.
    • 16. Mylab Discovery Solutions Pvt. Ltd.
    • 17. OraSure Technologies, Inc.
    • 18. Qiagen Inc
    • 19. Quest Consumer Inc.
    • 20. Sansure Biotech Inc.
    • 21. Seegene Inc.
    • 22. Siemens Healthcare GmbH
    • 23. Thermo Fisher Scientific, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦